Ontology type: schema:ScholarlyArticle
2004-05
AUTHORS ABSTRACTBackgroundβ2-Adrenoceptor agonists have been used as bronchodilators in the management of asthma and chronic obstructive pulmonary disease (COPD); however, there is evidence suggesting that β2-adrenoceptor agonist use may increase morbidity and mortality.MethodsA systematic review of case-control studies and randomised controlled trials was performed to evaluate the cardiovascular safety of β2-adrenoceptor agonist use in patients with obstructive airway disease, defined as asthma or COPD.ResultsCase-control studies have shown that β2-adrenoceptor agonist use is associated with an increased risk of myocardial infarction, congestive heart failure, cardiac arrest and sudden cardiac death. The degree of risk appears to be dose-dependent, and may be highest for new users and those with concomitant cardiac conditions. Pooled data from randomised placebo-controlled trials indicate that β2-adrenoceptor agonist use increases the risk of adverse cardiovascular events by more than 2-fold compared with placebo, thus providing evidence that the association seen in case-control studies is a causal one. Single doses of β2-adrenoceptor agonists significantly increase heart rate and decrease potassium concentrations compared with placebo.ConclusionsInitiation of β2-adrenoceptor agonist treatment increases heart rate and decreases potassium concentrations, while continued use may increase the risk of adverse cardiovascular events. It could be through these effects of β-adrenergic stimulation that β2-adrenoceptor agonists may induce ischaemia, congestive heart failure, arrhythmias and sudden cardiac death. In addition to increasing adverse cardiovascular events, β2-adrenoceptor agonist use may induce respiratory tolerance and increase the risk of asthma attacks. It is not clear whether β2-adrenoceptor agonists should be used regularly in the treatment of obstructive airway disease, with or without concomitant cardiovascular disease. More... »
PAGES405-414
http://scigraph.springernature.com/pub.10.2165/00002512-200421060-00005
DOIhttp://dx.doi.org/10.2165/00002512-200421060-00005
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1044511580
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/15084142
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Cardiorespiratory Medicine and Haematology",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adrenergic alpha-2 Receptor Agonists",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adrenergic beta-Agonists",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Animals",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Asthma",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Cardiovascular Diseases",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Case-Control Studies",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Pulmonary Disease, Chronic Obstructive",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Randomized Controlled Trials as Topic",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Santa Clara Valley Medical Center, 751 S. Bascom Ave, 95128, San Jose, CA, USA",
"id": "http://www.grid.ac/institutes/grid.415182.b",
"name": [
"Stanford University School of Medicine, Stanford, California, USA",
"Santa Clara Valley Medical Center, 751 S. Bascom Ave, 95128, San Jose, CA, USA"
],
"type": "Organization"
},
"familyName": "Salpeter",
"givenName": "Shelley R.",
"id": "sg:person.012160071167.38",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012160071167.38"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.2165/00003495-199142030-00007",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1021698570",
"https://doi.org/10.2165/00003495-199142030-00007"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.2165/00002018-199207010-00007",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1053525213",
"https://doi.org/10.2165/00002018-199207010-00007"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s002280050435",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1050389605",
"https://doi.org/10.1007/s002280050435"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.2165/00003495-197600111-00025",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1045796379",
"https://doi.org/10.2165/00003495-197600111-00025"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/bf00614551",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1009739834",
"https://doi.org/10.1007/bf00614551"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s002280050399",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1042256952",
"https://doi.org/10.1007/s002280050399"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/bf03259844",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1037870887",
"https://doi.org/10.1007/bf03259844"
],
"type": "CreativeWork"
}
],
"datePublished": "2004-05",
"datePublishedReg": "2004-05-01",
"description": "Background\u03b22-Adrenoceptor agonists have been used as bronchodilators in the management of asthma and chronic obstructive pulmonary disease (COPD); however, there is evidence suggesting that \u03b22-adrenoceptor agonist use may increase morbidity and mortality.MethodsA systematic review of case-control studies and randomised controlled trials was performed to evaluate the cardiovascular safety of \u03b22-adrenoceptor agonist use in patients with obstructive airway disease, defined as asthma or COPD.ResultsCase-control studies have shown that \u03b22-adrenoceptor agonist use is associated with an increased risk of myocardial infarction, congestive heart failure, cardiac arrest and sudden cardiac death. The degree of risk appears to be dose-dependent, and may be highest for new users and those with concomitant cardiac conditions. Pooled data from randomised placebo-controlled trials indicate that \u03b22-adrenoceptor agonist use increases the risk of adverse cardiovascular events by more than 2-fold compared with placebo, thus providing evidence that the association seen in case-control studies is a causal one. Single doses of \u03b22-adrenoceptor agonists significantly increase heart rate and decrease potassium concentrations compared with placebo.ConclusionsInitiation of \u03b22-adrenoceptor agonist treatment increases heart rate and decreases potassium concentrations, while continued use may increase the risk of adverse cardiovascular events. It could be through these effects of \u03b2-adrenergic stimulation that \u03b22-adrenoceptor agonists may induce ischaemia, congestive heart failure, arrhythmias and sudden cardiac death. In addition to increasing adverse cardiovascular events, \u03b22-adrenoceptor agonist use may induce respiratory tolerance and increase the risk of asthma attacks. It is not clear whether \u03b22-adrenoceptor agonists should be used regularly in the treatment of obstructive airway disease, with or without concomitant cardiovascular disease.",
"genre": "article",
"id": "sg:pub.10.2165/00002512-200421060-00005",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1100990",
"issn": [
"1170-229X",
"1179-1969"
],
"name": "Drugs & Aging",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "6",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "21"
}
],
"keywords": [
"chronic obstructive pulmonary disease",
"adverse cardiovascular events",
"obstructive airways disease",
"\u03b22-adrenoceptor agonists",
"agonist use",
"congestive heart failure",
"sudden cardiac death",
"case-control study",
"cardiovascular events",
"airway disease",
"cardiovascular safety",
"heart failure",
"cardiac death",
"heart rate",
"concomitant cardiac conditions",
"placebo-controlled trial",
"concomitant cardiovascular disease",
"management of asthma",
"obstructive pulmonary disease",
"MethodsA systematic review",
"potassium concentration",
"pulmonary disease",
"agonist treatment",
"respiratory tolerance",
"cardiac arrest",
"asthma attacks",
"myocardial infarction",
"single doses",
"cardiovascular disease",
"cardiac conditions",
"adrenergic stimulation",
"systematic review",
"agonists",
"disease",
"placebo",
"asthma",
"patients",
"risk",
"trials",
"degree of risk",
"death",
"treatment",
"safety",
"bronchodilators",
"morbidity",
"ischaemia",
"infarction",
"failure",
"arrhythmias",
"mortality",
"doses",
"study",
"evidence",
"stimulation",
"arrest",
"events",
"causal one",
"association",
"use",
"rate",
"new users",
"review",
"concentration",
"management",
"effect",
"tolerance",
"data",
"addition",
"degree",
"attacks",
"conditions",
"one",
"users"
],
"name": "Cardiovascular Safety of \u03b22-Adrenoceptor Agonist Use in Patients with Obstructive Airway Disease",
"pagination": "405-414",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1044511580"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.2165/00002512-200421060-00005"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"15084142"
]
}
],
"sameAs": [
"https://doi.org/10.2165/00002512-200421060-00005",
"https://app.dimensions.ai/details/publication/pub.1044511580"
],
"sdDataset": "articles",
"sdDatePublished": "2022-08-04T16:55",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_390.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.2165/00002512-200421060-00005"
}
]
Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00002512-200421060-00005'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00002512-200421060-00005'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00002512-200421060-00005'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00002512-200421060-00005'
This table displays all metadata directly associated to this object as RDF triples.
199 TRIPLES
21 PREDICATES
115 URIs
100 LITERALS
16 BLANK NODES
Subject | Predicate | Object | |
---|---|---|---|
1 | sg:pub.10.2165/00002512-200421060-00005 | schema:about | N2f015628f4a44a428dce029c4ccccda9 |
2 | ″ | ″ | N3915ed9bb84b4644a3617365065b98f7 |
3 | ″ | ″ | N401dd3aafb4e4a1e82b1ac3192972f95 |
4 | ″ | ″ | N5d1007d3a2204c11946544cdd8e48858 |
5 | ″ | ″ | N5dd318da02c948cd9cd3fb16fa6ee1d6 |
6 | ″ | ″ | N98e13b587ad644e8ac217409c1284550 |
7 | ″ | ″ | Nbd64adb3685d48209e44b9df3b9be729 |
8 | ″ | ″ | Nc7b30d23bb12413ebfbc339e9f95b7aa |
9 | ″ | ″ | Ncc60b535cef546ba9ee55e3e73b5dd93 |
10 | ″ | ″ | anzsrc-for:11 |
11 | ″ | ″ | anzsrc-for:1102 |
12 | ″ | schema:author | Nf14e2cfd53ab4d2fb3f80f571fe6a466 |
13 | ″ | schema:citation | sg:pub.10.1007/bf00614551 |
14 | ″ | ″ | sg:pub.10.1007/bf03259844 |
15 | ″ | ″ | sg:pub.10.1007/s002280050399 |
16 | ″ | ″ | sg:pub.10.1007/s002280050435 |
17 | ″ | ″ | sg:pub.10.2165/00002018-199207010-00007 |
18 | ″ | ″ | sg:pub.10.2165/00003495-197600111-00025 |
19 | ″ | ″ | sg:pub.10.2165/00003495-199142030-00007 |
20 | ″ | schema:datePublished | 2004-05 |
21 | ″ | schema:datePublishedReg | 2004-05-01 |
22 | ″ | schema:description | Backgroundβ2-Adrenoceptor agonists have been used as bronchodilators in the management of asthma and chronic obstructive pulmonary disease (COPD); however, there is evidence suggesting that β2-adrenoceptor agonist use may increase morbidity and mortality.MethodsA systematic review of case-control studies and randomised controlled trials was performed to evaluate the cardiovascular safety of β2-adrenoceptor agonist use in patients with obstructive airway disease, defined as asthma or COPD.ResultsCase-control studies have shown that β2-adrenoceptor agonist use is associated with an increased risk of myocardial infarction, congestive heart failure, cardiac arrest and sudden cardiac death. The degree of risk appears to be dose-dependent, and may be highest for new users and those with concomitant cardiac conditions. Pooled data from randomised placebo-controlled trials indicate that β2-adrenoceptor agonist use increases the risk of adverse cardiovascular events by more than 2-fold compared with placebo, thus providing evidence that the association seen in case-control studies is a causal one. Single doses of β2-adrenoceptor agonists significantly increase heart rate and decrease potassium concentrations compared with placebo.ConclusionsInitiation of β2-adrenoceptor agonist treatment increases heart rate and decreases potassium concentrations, while continued use may increase the risk of adverse cardiovascular events. It could be through these effects of β-adrenergic stimulation that β2-adrenoceptor agonists may induce ischaemia, congestive heart failure, arrhythmias and sudden cardiac death. In addition to increasing adverse cardiovascular events, β2-adrenoceptor agonist use may induce respiratory tolerance and increase the risk of asthma attacks. It is not clear whether β2-adrenoceptor agonists should be used regularly in the treatment of obstructive airway disease, with or without concomitant cardiovascular disease. |
23 | ″ | schema:genre | article |
24 | ″ | schema:isAccessibleForFree | false |
25 | ″ | schema:isPartOf | N1ac832ff52c948f28b968b46884fddc9 |
26 | ″ | ″ | N3eab9cea3fc842829600c56230888632 |
27 | ″ | ″ | sg:journal.1100990 |
28 | ″ | schema:keywords | MethodsA systematic review |
29 | ″ | ″ | addition |
30 | ″ | ″ | adrenergic stimulation |
31 | ″ | ″ | adverse cardiovascular events |
32 | ″ | ″ | agonist treatment |
33 | ″ | ″ | agonist use |
34 | ″ | ″ | agonists |
35 | ″ | ″ | airway disease |
36 | ″ | ″ | arrest |
37 | ″ | ″ | arrhythmias |
38 | ″ | ″ | association |
39 | ″ | ″ | asthma |
40 | ″ | ″ | asthma attacks |
41 | ″ | ″ | attacks |
42 | ″ | ″ | bronchodilators |
43 | ″ | ″ | cardiac arrest |
44 | ″ | ″ | cardiac conditions |
45 | ″ | ″ | cardiac death |
46 | ″ | ″ | cardiovascular disease |
47 | ″ | ″ | cardiovascular events |
48 | ″ | ″ | cardiovascular safety |
49 | ″ | ″ | case-control study |
50 | ″ | ″ | causal one |
51 | ″ | ″ | chronic obstructive pulmonary disease |
52 | ″ | ″ | concentration |
53 | ″ | ″ | concomitant cardiac conditions |
54 | ″ | ″ | concomitant cardiovascular disease |
55 | ″ | ″ | conditions |
56 | ″ | ″ | congestive heart failure |
57 | ″ | ″ | data |
58 | ″ | ″ | death |
59 | ″ | ″ | degree |
60 | ″ | ″ | degree of risk |
61 | ″ | ″ | disease |
62 | ″ | ″ | doses |
63 | ″ | ″ | effect |
64 | ″ | ″ | events |
65 | ″ | ″ | evidence |
66 | ″ | ″ | failure |
67 | ″ | ″ | heart failure |
68 | ″ | ″ | heart rate |
69 | ″ | ″ | infarction |
70 | ″ | ″ | ischaemia |
71 | ″ | ″ | management |
72 | ″ | ″ | management of asthma |
73 | ″ | ″ | morbidity |
74 | ″ | ″ | mortality |
75 | ″ | ″ | myocardial infarction |
76 | ″ | ″ | new users |
77 | ″ | ″ | obstructive airways disease |
78 | ″ | ″ | obstructive pulmonary disease |
79 | ″ | ″ | one |
80 | ″ | ″ | patients |
81 | ″ | ″ | placebo |
82 | ″ | ″ | placebo-controlled trial |
83 | ″ | ″ | potassium concentration |
84 | ″ | ″ | pulmonary disease |
85 | ″ | ″ | rate |
86 | ″ | ″ | respiratory tolerance |
87 | ″ | ″ | review |
88 | ″ | ″ | risk |
89 | ″ | ″ | safety |
90 | ″ | ″ | single doses |
91 | ″ | ″ | stimulation |
92 | ″ | ″ | study |
93 | ″ | ″ | sudden cardiac death |
94 | ″ | ″ | systematic review |
95 | ″ | ″ | tolerance |
96 | ″ | ″ | treatment |
97 | ″ | ″ | trials |
98 | ″ | ″ | use |
99 | ″ | ″ | users |
100 | ″ | ″ | β2-adrenoceptor agonists |
101 | ″ | schema:name | Cardiovascular Safety of β2-Adrenoceptor Agonist Use in Patients with Obstructive Airway Disease |
102 | ″ | schema:pagination | 405-414 |
103 | ″ | schema:productId | N6fcc3891bbb94976904fba003cf0f70f |
104 | ″ | ″ | N8c9d8cb869084385a11f1e13fbcfeda2 |
105 | ″ | ″ | N963d3333e2c24f59966c2528b0f7529b |
106 | ″ | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1044511580 |
107 | ″ | ″ | https://doi.org/10.2165/00002512-200421060-00005 |
108 | ″ | schema:sdDatePublished | 2022-08-04T16:55 |
109 | ″ | schema:sdLicense | https://scigraph.springernature.com/explorer/license/ |
110 | ″ | schema:sdPublisher | N849af56899f04f478f7b524a49600628 |
111 | ″ | schema:url | https://doi.org/10.2165/00002512-200421060-00005 |
112 | ″ | sgo:license | sg:explorer/license/ |
113 | ″ | sgo:sdDataset | articles |
114 | ″ | rdf:type | schema:ScholarlyArticle |
115 | N1ac832ff52c948f28b968b46884fddc9 | schema:volumeNumber | 21 |
116 | ″ | rdf:type | schema:PublicationVolume |
117 | N2f015628f4a44a428dce029c4ccccda9 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
118 | ″ | schema:name | Pulmonary Disease, Chronic Obstructive |
119 | ″ | rdf:type | schema:DefinedTerm |
120 | N3915ed9bb84b4644a3617365065b98f7 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
121 | ″ | schema:name | Adrenergic alpha-2 Receptor Agonists |
122 | ″ | rdf:type | schema:DefinedTerm |
123 | N3eab9cea3fc842829600c56230888632 | schema:issueNumber | 6 |
124 | ″ | rdf:type | schema:PublicationIssue |
125 | N401dd3aafb4e4a1e82b1ac3192972f95 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
126 | ″ | schema:name | Asthma |
127 | ″ | rdf:type | schema:DefinedTerm |
128 | N5d1007d3a2204c11946544cdd8e48858 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
129 | ″ | schema:name | Animals |
130 | ″ | rdf:type | schema:DefinedTerm |
131 | N5dd318da02c948cd9cd3fb16fa6ee1d6 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
132 | ″ | schema:name | Cardiovascular Diseases |
133 | ″ | rdf:type | schema:DefinedTerm |
134 | N6fcc3891bbb94976904fba003cf0f70f | schema:name | dimensions_id |
135 | ″ | schema:value | pub.1044511580 |
136 | ″ | rdf:type | schema:PropertyValue |
137 | N849af56899f04f478f7b524a49600628 | schema:name | Springer Nature - SN SciGraph project |
138 | ″ | rdf:type | schema:Organization |
139 | N8c9d8cb869084385a11f1e13fbcfeda2 | schema:name | pubmed_id |
140 | ″ | schema:value | 15084142 |
141 | ″ | rdf:type | schema:PropertyValue |
142 | N963d3333e2c24f59966c2528b0f7529b | schema:name | doi |
143 | ″ | schema:value | 10.2165/00002512-200421060-00005 |
144 | ″ | rdf:type | schema:PropertyValue |
145 | N98e13b587ad644e8ac217409c1284550 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
146 | ″ | schema:name | Adrenergic beta-Agonists |
147 | ″ | rdf:type | schema:DefinedTerm |
148 | Nbd64adb3685d48209e44b9df3b9be729 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
149 | ″ | schema:name | Randomized Controlled Trials as Topic |
150 | ″ | rdf:type | schema:DefinedTerm |
151 | Nc7b30d23bb12413ebfbc339e9f95b7aa | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
152 | ″ | schema:name | Humans |
153 | ″ | rdf:type | schema:DefinedTerm |
154 | Ncc60b535cef546ba9ee55e3e73b5dd93 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
155 | ″ | schema:name | Case-Control Studies |
156 | ″ | rdf:type | schema:DefinedTerm |
157 | Nf14e2cfd53ab4d2fb3f80f571fe6a466 | rdf:first | sg:person.012160071167.38 |
158 | ″ | rdf:rest | rdf:nil |
159 | anzsrc-for:11 | schema:inDefinedTermSet | anzsrc-for: |
160 | ″ | schema:name | Medical and Health Sciences |
161 | ″ | rdf:type | schema:DefinedTerm |
162 | anzsrc-for:1102 | schema:inDefinedTermSet | anzsrc-for: |
163 | ″ | schema:name | Cardiorespiratory Medicine and Haematology |
164 | ″ | rdf:type | schema:DefinedTerm |
165 | sg:journal.1100990 | schema:issn | 1170-229X |
166 | ″ | ″ | 1179-1969 |
167 | ″ | schema:name | Drugs & Aging |
168 | ″ | schema:publisher | Springer Nature |
169 | ″ | rdf:type | schema:Periodical |
170 | sg:person.012160071167.38 | schema:affiliation | grid-institutes:grid.415182.b |
171 | ″ | schema:familyName | Salpeter |
172 | ″ | schema:givenName | Shelley R. |
173 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012160071167.38 |
174 | ″ | rdf:type | schema:Person |
175 | sg:pub.10.1007/bf00614551 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1009739834 |
176 | ″ | ″ | https://doi.org/10.1007/bf00614551 |
177 | ″ | rdf:type | schema:CreativeWork |
178 | sg:pub.10.1007/bf03259844 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1037870887 |
179 | ″ | ″ | https://doi.org/10.1007/bf03259844 |
180 | ″ | rdf:type | schema:CreativeWork |
181 | sg:pub.10.1007/s002280050399 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1042256952 |
182 | ″ | ″ | https://doi.org/10.1007/s002280050399 |
183 | ″ | rdf:type | schema:CreativeWork |
184 | sg:pub.10.1007/s002280050435 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1050389605 |
185 | ″ | ″ | https://doi.org/10.1007/s002280050435 |
186 | ″ | rdf:type | schema:CreativeWork |
187 | sg:pub.10.2165/00002018-199207010-00007 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1053525213 |
188 | ″ | ″ | https://doi.org/10.2165/00002018-199207010-00007 |
189 | ″ | rdf:type | schema:CreativeWork |
190 | sg:pub.10.2165/00003495-197600111-00025 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1045796379 |
191 | ″ | ″ | https://doi.org/10.2165/00003495-197600111-00025 |
192 | ″ | rdf:type | schema:CreativeWork |
193 | sg:pub.10.2165/00003495-199142030-00007 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1021698570 |
194 | ″ | ″ | https://doi.org/10.2165/00003495-199142030-00007 |
195 | ″ | rdf:type | schema:CreativeWork |
196 | grid-institutes:grid.415182.b | schema:alternateName | Santa Clara Valley Medical Center, 751 S. Bascom Ave, 95128, San Jose, CA, USA |
197 | ″ | schema:name | Santa Clara Valley Medical Center, 751 S. Bascom Ave, 95128, San Jose, CA, USA |
198 | ″ | ″ | Stanford University School of Medicine, Stanford, California, USA |
199 | ″ | rdf:type | schema:Organization |